Skip to main content

Peer Review reports

From: Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

Original Submission
15 Apr 2022 Submitted Original manuscript
3 May 2022 Reviewed Reviewer Report
5 May 2022 Reviewed Reviewer Report
2 Jun 2022 Author responded Author comments - Pepa Polavieja
Resubmission - Version 2
2 Jun 2022 Submitted Manuscript version 2
4 Jun 2022 Editorially accepted
6 Jul 2022 Article published 10.1186/s10194-022-01440-w

You can find further information about peer review here.

Back to article page